Canaccord Genuity Reiterates Buy Rating on Clover Health Investments, Keeps PT at $4.10

Group 1 - Clover Health Investments, Corp. (NASDAQ:CLOV) is recognized as one of the 12 best NASDAQ penny stocks to buy according to hedge funds [1] - Canaccord Genuity has reiterated a Buy rating on Clover Health with a price target of $4.10, anticipating benefits from projected 9.04% growth in 2026 Medicare Advantage rates [1][2] - The company's top-rated PPO plan is expected to enhance revenue per member, providing a significant growth opportunity [1] Group 2 - Clover Health has shown effective cost management strategies, particularly in managing Part A and Part B expenditures, despite challenges with increased Part D drug spending [2] - The potential for membership growth in 2026 supports a positive outlook for Clover Health [2] - Clover Health offers Medicare Advantage plans in the U.S., serving both preferred provider organization and health maintenance organization plans to Medicare-eligible individuals [3] Group 3 - Clover's subsidiary, Counterpart Health, announced a major upgrade to its Counterpart Assistant, enhancing the integrated ambient scribing solution to improve physician experience [1]